Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Najwa Somani"'
Autor:
Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 1007-1018 (2024)
Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat wit
Externí odkaz:
https://doaj.org/article/2172459873774bdcb1e836294768df9a
Autor:
Susan Taylor, Neil J. Korman, Tsen-Fang Tsai, Yutaka Shimomura, Meghan Feely, Yves Dutronc, Wen-Shuo Wu, Najwa Somani, Antonella Tosti
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3181-3191 (2023)
Abstract Background Baricitinib, an oral selective JAK1/JAK2 inhibitor, is approved for the treatment of adults with severe alopecia areata (AA). Objective To evaluate differences in response up to week 52 among subgroups based on the baseline severi
Externí odkaz:
https://doaj.org/article/ec3994a4004f469cadd3311b93a0b34b
Autor:
Antonio Costanzo, Akio Tanaka, Tiago Torres, Bibiana Pérez‐García, Angelina Sontag, Yun‐Fei Chen, Fan Emily Yang, Jill Kolodsick, Hitoe Torisu‐Itakura, Najwa Somani
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 3, Pp 583-589 (2023)
Abstract Background The Janus kinase (JAK)1/JAK2 inhibitor baricitinib in combination with topical corticosteroids (TCS) improved moderate‐to‐severe atopic dermatitis (AD) in the phase 3 BREEZE‐AD7 trial. Patients with previous systemic therapy
Externí odkaz:
https://doaj.org/article/28b5947c538643a1a51dcdf95cb32f88
Autor:
Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 2, Pp 282-292 (2023)
Abstract Background People with genital psoriasis may avoid close social interactions (hugs, handshakes, kisses, touching others, or being touched), which can have a significant impact on quality of life. Ixekizumab, an interleukin 17A antagonist, de
Externí odkaz:
https://doaj.org/article/ffcd1adcd24c46c0986747258116f460
Autor:
Andrew Blauvelt, Nianwen Shi, Najwa Somani, Russel Burge, Baojin Zhu, Terri Ridenour, Scott Kern, Carolyn Lew, Nicole Zimmerman, Mwangi Murage
Publikováno v:
Clinical Drug Investigation. 43:185-196
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a230e9376293242028f047d0a75ded65
https://doi.org/10.1007/s40261-022-01240-9
https://doi.org/10.1007/s40261-022-01240-9
Autor:
Adelaide A, Hebert, Margaret A, Bobonich, Claudia, Rodriguez Capriles, Gaia, Gallo, Lingnan, Li, Najwa, Somani, Terri, Ridenour, Yan, Wang, Emily, Edson-Heredia, Emily M, Becker
Publikováno v:
Pediatric Dermatology. 39:55-60
Information is limited on the relationship between skin clearance, resolution of challenging body areas, and improvement of patient-reported outcomes (PROs) in pediatric psoriasis. Ixekizumab, a high-affinity monoclonal antibody that selectively targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c99349ee0be6fe2888d621287536be
https://doi.org/10.1111/pde.14892
https://doi.org/10.1111/pde.14892
Autor:
Andrew Blauvelt, Nianwen Shi, Russel Burge, Bilal Atiya, Baojin Zhu, Najwa Somani, Terri Ridenour, Carolyn R. Lew, Nicole M. Zimmerman, Mwangi J. Murage
Publikováno v:
PharmacoEconomics - open. 6(6)
The aim of this study was to compare healthcare costs between ixekizumab (IXE)-treated and secukinumab (SEC)-treated patients with psoriasis over a 24-month follow-up period in the United States.Patients with psoriasis diagnosis were identified from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bc061edfef07a5f05b2b9d18067e07f
https://pubmed.ncbi.nlm.nih.gov/36155891
https://pubmed.ncbi.nlm.nih.gov/36155891
Autor:
Brett King, Jerry Shapiro, Manabu Ohyama, Alexander Egeberg, Yves Dutronc, Yun-Fei Chen, Wen-Shuo Wu, Yuxin Ding, Najwa Somani, Rodney Sinclair
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s184
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7da1e44aff7fcf2e141a4c5dff6132fd
https://doi.org/10.25251/skin.7.supp.184
https://doi.org/10.25251/skin.7.supp.184
Autor:
Andrew Blauvelt, Nianwen Shi, Mwangi J. Murage, Scott A. Kern, Najwa Somani, Russel Burge, Terri L. Ridenour, Carolyn R. Lew, Nicole M. Zimmerman, Baojin Zhu
Publikováno v:
Journal of medical economics. 25(1)
To compare long-term healthcare resource utilization (HCRU) and costs among patients who initiated ixekizumab (IXE) or adalimumab (ADA) for treatment of psoriasis in the United States.Adult patients with psoriasis who had ≥1 claim for IXE or ADA we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942323cde03a7134d4614f78bb246a12
https://pubmed.ncbi.nlm.nih.gov/35615978
https://pubmed.ncbi.nlm.nih.gov/35615978
Autor:
Andrew, Blauvelt, Nianwen, Shi, Mwangi, Murage, Terri, Ridenour, Carolyn, Lew, Najwa, Somani, Baojin, Zhu, Nicole, Zimmerman, Scott, Kern, Russel, Burge
Publikováno v:
Journal of drugs in dermatology : JDD. 21(4)
There is a paucity of long-term real-world evidence comparing the effectiveness of ixekizumab (IXE) and adalimumab (ADA). We compared real-world treatment patterns of IXE-treated and ADA-treated patients with psoriasis over 24 months in the United St
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3bf177b54f00a64bec83ca427e2cf479
https://pubmed.ncbi.nlm.nih.gov/35389589
https://pubmed.ncbi.nlm.nih.gov/35389589